Vertex Pharmaceuticals
- Market cap
- 128.16B
- P/E (TTM)i
- 29.45
- P/Bi
- 6.33
- EPSi
- 15.32
- Div yieldi
- 0.00%
- 52W posi
- 65%
Anonymous reader poll. Unscientific, not investment advice.
Vertex Pharmaceuticals ended the session at 505.64, up 0.66%. That leaves the company valued at approximately 128.16B, the #155 most valuable US-listed company we track. The 24 analysts covering the stock are, on balance, at Buy, targeting an average of 580.21 (+15%). The shares sit 65% of the way up their 52-week range of 402.58 to 560.25.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 week.
- Recent price momentum is +10.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 29.3x | Better than 28% |
| Forward P/E | 52.1x | Better than 8% |
| Price / Sales | 10.3x | Better than 12% |
| P/E vs own 5-yr range | 79th pctl | Better than 28% |
Growth B-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.4% | Better than 66% |
| Net income CAGR (3Y) | 6.0% | Better than 51% |
| Free cash flow CAGR (3Y) | -6.6% | Better than 26% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 86.2% | Better than 96% |
| Operating margin | 37.9% | Better than 92% |
| Net margin | 32.9% | Better than 93% |
| Return on equity | 22.5% | Better than 72% |
| Return on invested capital | 18.3% | Better than 81% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -3.6% | Better than 45% |
| 6-month return | 16.6% | Better than 67% |
| 12-month return (ex latest month) | 35.5% | Better than 70% |
| Distance below 52-week high | 10.1% | Better than 76% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.9x | Better than 81% |
| Debt to assets | 10.9% | Better than 76% |
| Interest coverage | 350.1x | Better than 97% |
| Free cash flow / net income | 80.8% | Better than 26% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 87.5% | Better than 69% |
| Upside to average target | 15.2% | Better than 27% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 502.31
- Open
- 504.08
- Day range
- 503.94 - 511.51
- Avg price
- 506.81
- Volume
- 806.84K
- Turnover
- 408.92M
- Turnover ratei
- 0.32%
- Volume ratioi
- 0.81
- Amplitudei
- 1.51%
- 52-week rangei
- 402.58 - 560.25
Valuation
- P/Ei
- 33.01
- P/E (TTM)i
- 29.45
- P/Bi
- 6.33
- EPSi
- 15.32
- Book value / shi
- 79.89
- Net profit
- 3.88B
- Net assets
- 20.25B
Share structure
- Market cap
- 128.16B
- Float capi
- 127.77B
- Shares out
- 253.46M
- Float sharesi
- 252.68M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
9.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+79.34M net over the window
Short interest
- Shares short
- 4.72M
- % of floati
- 1.86%
- Days to coveri
- 5.03
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Vertex Pharmaceuticals (VRTX)?
Vertex Pharmaceuticals last traded at 505.64. The quote on this page refreshes every few seconds while US markets are open.
What is Vertex Pharmaceuticals's market cap?
About 128.16B.
What is the P/E ratio of Vertex Pharmaceuticals?
The trailing twelve-month P/E is 29.45. The Valuation tab shows it against the stock's own five-year range.
Does Vertex Pharmaceuticals pay a dividend?
Vertex Pharmaceuticals does not currently pay a regular dividend.
Is Vertex Pharmaceuticals a buy according to analysts?
The consensus of 24 analysts is a Buy rating, with an average 12-month price target of 580.21, which implies 14.7% upside from the current price. This is not investment advice.
What is Vertex Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Vertex Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 07:02:25 · For reference only, not investment advice and not tailored to your situation.